<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503851</url>
  </required_header>
  <id_info>
    <org_study_id>#3150</org_study_id>
    <nct_id>NCT03503851</nct_id>
  </id_info>
  <brief_title>Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation</brief_title>
  <acronym>One-Plus-One</acronym>
  <official_title>Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation (One-Plus-One)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios proresearch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepios proresearch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implantation of the MitraClip has become the most frequently used percutaneous technique to
      treat significant (grade 3+ or 4+) mitral regurgitation (MR) in elderly patients deemed
      inoperable or at high surgical risk. In Europe, about two-thirds of patients treated with the
      MitraClip suffer from MR of functional origin secondary to ischemic or dilated
      cardiomyopathy. At present, there is debate among operators on whether stabilizing/supporting
      a single adequately implanted clip with a second clip is beneficial for patients with
      functional MR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantation of the MitraClip has become the most frequently used percutaneous technique to
      treat significant (grade 3+ or 4+) mitral regurgitation (MR) in elderly patients deemed
      inoperable or at high surgical risk. In Europe, about two-thirds of patients treated with the
      MitraClip suffer from MR of functional origin secondary to ischemic or dilated
      cardiomyopathy. At present, there is debate among operators on whether stabilizing/supporting
      a single adequately implanted clip with a second clip is beneficial for patients with
      functional MR.

      Purpose To demonstrate the noninferiority of a 1-clip strategy vs. a 2-clip strategy of
      MitraClip implantation, when the second clip in the 2-clip study arm is implanted for
      stabilizing/supporting purposes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, randomized, parallel-arm trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of number of participants who died death within one year</measure>
    <time_frame>1 year</time_frame>
    <description>death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of number of rehospitalizations due to heart failure among patients receiving one or two clips</measure>
    <time_frame>1 year</time_frame>
    <description>heart failure rehospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of number of participants with recurrent regurgitation within one year</measure>
    <time_frame>1 year</time_frame>
    <description>recurrence of mitral regurgitation (&gt;grade 2+ at 1 year)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>1 year</time_frame>
    <description>freedom from death (1-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>freedom from heart failure (1-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization</measure>
    <time_frame>1-year</time_frame>
    <description>rehospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regurgitation</measure>
    <time_frame>1-year</time_frame>
    <description>freedom from recurrence of mitral regurgitation (&gt;2+; 1-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success rate</measure>
    <time_frame>1-year</time_frame>
    <description>procedural success rate in 2-clip arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure duration</measure>
    <time_frame>1-year</time_frame>
    <description>procedure duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total device time</measure>
    <time_frame>1-year</time_frame>
    <description>total device time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluoroscopy time</measure>
    <time_frame>1-year</time_frame>
    <description>fluoroscopy time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast volume</measure>
    <time_frame>1-year</time_frame>
    <description>contrast volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>1-year</time_frame>
    <description>periprocedural (30-day) complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic variables</measure>
    <time_frame>1-year</time_frame>
    <description>The following echocardiographic variables will be assessed by 2-dimensional transthoracic echocardiography at 12 months: Left ventricular (LV) end-diastolic diameter and volume; LV end-systolic diameter and volume; LV ejection fraction; LV outflow tract diameter and velocity time integral in LV outflow tract (to calculate forward stroke volume).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in echocardiographic variables</measure>
    <time_frame>1-year</time_frame>
    <description>Changes from baseline to 12 months in echocardiographically assessed (at both time points) LV end-diastolic diameter and volume; LV end-systolic diameter and volume; LV ejection fraction; and forward stroke volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA</measure>
    <time_frame>1-year</time_frame>
    <description>NYHA functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minutes walk</measure>
    <time_frame>1-year</time_frame>
    <description>6-minutes walk distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1-year</time_frame>
    <description>Assessment of the Minnesota Living With Heart Failure Questionnaire (MLHFQ) quality-of-life score. The questionnaire consists of 21 quality-of-life questions to be answered by the patient on a grading scale of 0 (best) to 5 (worst). Thus, the overall MLHFQ score ranges from 0 to 105.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Mitral Regurgitation Functional</condition>
  <arm_group>
    <arm_group_label>One CLIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of single MitraClip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two CLIPs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of second MitraClip (after successful Implantation of single MitraClip)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip implantation</intervention_name>
    <description>Device to approximate the mitral valve leaflets</description>
    <arm_group_label>One CLIP</arm_group_label>
    <arm_group_label>Two CLIPs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Absence of a structural abnormality of the mitral valve giving rise to MR.

          -  MR severity of US grade 3+ or 4+ of central or noncentral origin

          -  Patient must consent to randomization in the hybrid operating theater upon successful
             implantation of a single MitraClip. Written informed consent must be provided prior to
             the MitraClip procedure.

        Exclusion Criteria:

          -  patients with primary regurgitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg, Dept. of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Frerker, MD, PHD</last_name>
    <phone>+49-40-181885-4429</phone>
    <email>c.frerker@asklepios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kai Jaquet, PHD, DSc</last_name>
    <phone>+49-40-181885-4468</phone>
    <email>k.jaquet@asklepios.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed</url>
  </link>
  <reference>
    <citation>Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wang A, Glower DD, Mauri L; EVEREST II Investigators. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. 2015 Dec 29;66(25):2844-2854. doi: 10.1016/j.jacc.2015.10.018.</citation>
    <PMID>26718672</PMID>
  </reference>
  <reference>
    <citation>Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011 Apr 14;364(15):1395-406. doi: 10.1056/NEJMoa1009355. Epub 2011 Apr 4. Erratum in: N Engl J Med. 2011 Jul 14;365(2):189. Glower, Donald G [corrected to Glower, Donald D].</citation>
    <PMID>21463154</PMID>
  </reference>
  <reference>
    <citation>Franzen O, Baldus S, Rudolph V, Meyer S, Knap M, Koschyk D, Treede H, Barmeyer A, Schofer J, Costard-Jäckle A, Schlüter M, Reichenspurner H, Meinertz T. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J. 2010 Jun;31(11):1373-81. doi: 10.1093/eurheartj/ehq050. Epub 2010 Mar 10.</citation>
    <PMID>20219746</PMID>
  </reference>
  <reference>
    <citation>Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Möllmann H, Hehrlein C, Ouarrak T, Senges J, Meinertz T; German Transcatheter Mitral Valve Interventions (TRAMI) investigators. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012 Sep;14(9):1050-5. Epub 2012 Jun 8.</citation>
    <PMID>22685268</PMID>
  </reference>
  <reference>
    <citation>Grasso C, Capodanno D, Scandura S, Cannata S, Immè S, Mangiafico S, Pistritto A, Ministeri M, Barbanti M, Caggegi A, Chiarandà M, Dipasqua F, Giaquinta S, Occhipinti M, Ussia G, Tamburino C. One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP Registry). Am J Cardiol. 2013 May 15;111(10):1482-7. doi: 10.1016/j.amjcard.2013.01.300. Epub 2013 Feb 20.</citation>
    <PMID>23433761</PMID>
  </reference>
  <reference>
    <citation>Sürder D, Pedrazzini G, Gaemperli O, Biaggi P, Felix C, Rufibach K, der Maur CA, Jeger R, Buser P, Kaufmann BA, Moccetti M, Hürlimann D, Bühler I, Bettex D, Scherman J, Pasotti E, Faletra FF, Zuber M, Moccetti T, Lüscher TF, Erne P, Grünenfelder J, Corti R. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. Heart. 2013 Jul;99(14):1034-40. doi: 10.1136/heartjnl-2012-303105. Epub 2013 Jan 23.</citation>
    <PMID>23343688</PMID>
  </reference>
  <reference>
    <citation>Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder JD, Moccetti T, Schillinger W. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013 Sep 17;62(12):1052-1061. doi: 10.1016/j.jacc.2013.02.094. Epub 2013 Jun 7.</citation>
    <PMID>23747789</PMID>
  </reference>
  <reference>
    <citation>Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, Lüscher TF, Moat N, Price S, Dall'Ara G, Winter R, Corti R, Grasso C, Snow TM, Jeger R, Blankenberg S, Settergren M, Tiroch K, Balzer J, Petronio AS, Büttner HJ, Ettori F, Sievert H, Fiorino MG, Claeys M, Ussia GP, Baumgartner H, Scandura S, Alamgir F, Keshavarzi F, Colombo A, Maisano F, Ebelt H, Aruta P, Lubos E, Plicht B, Schueler R, Pighi M, Di Mario C; Transcatheter Valve Treatment Sentinel Registry Investigators of the EURObservational Research Programme of the European Society of Cardiology. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014 Sep 2;64(9):875-84. doi: 10.1016/j.jacc.2014.06.1166.</citation>
    <PMID>25169171</PMID>
  </reference>
  <reference>
    <citation>Eggebrecht H, Schelle S, Puls M, Plicht B, von Bardeleben RS, Butter C, May AE, Lubos E, Boekstegers P, Ouarrak T, Senges J, Schmermund A. Risk and outcomes of complications during and after MitraClip implantation: Experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv. 2015 Oct;86(4):728-35. doi: 10.1002/ccd.25838. Epub 2015 Feb 12.</citation>
    <PMID>25601532</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>transcatheter mitral valve repair</keyword>
  <keyword>MitraClip</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

